,i #aaith ,,congress #b;d ,session ,h4 ,r4 #ihbc ,,in ,,the ,,house ,,of ,,representatives ,july #bb1 #bjbf,mr4 ,auchincloss 7for himself and ,mr4 ,ciscomani7 introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce ,a ,,bill ,to amend title ,,xxvii of the ,public ,health ,service ,act and title ,,xix of the ,social ,security ,act to require coverage of ,alzheimer's biomarker testing under group health plans1 group and individual health insurance coverage1 and the ,medicaid program4 #a4 ,short title ,this ,act may be cited as the ,alzheimer's ,early ,detection ,act of #bjbf4 #b4 ,requiring coverage of ,alzheimer's biomarker testing under group health plans1 group and individual health insurance coverage1 and the ,medicaid program 7a7 ,private insurance 7#a7 ,in general ,part ,a of title ,,xxvii of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #cjj;gg-#aa et seq47 is amended by adding at the end the following new section3 #bgcj4 ,required coverage of ,alzheimer's biomarker testing 7a7 ,in general ,a group health plan and a health insurance issuer offering group or individual health insurance coverage shall provide benefits under such plan or coverage for ,alzherimer's biomarker testing4 7b7 ,manner of coverage ,a group health plan and a health insurance issuer offering group or individual health insurance coverage shall ensure that1 with respect to testing for which benefits are required to be provided under such plan or coverage under subsection 7a7-- 7#a7 the financial requirements applicable to such testing are no more restrictive than the predominant financial requirements applied to substantially all medical and surgical benefits covered by the plan or coverage and there are no separate cost-sharing requirements that are applicable only with respect to such testing2 7#b7 the treatment limitations applicable to such testing are no more restrictive than the predominant treatment limitations applied to substantially all medical and surgical benefits covered by the plan or coverage and there are no separate treatment limitations that are applicable only with respect to such testing2 7#c7 in the case such plan or coverage imposes any prior authorization requirement with respect to such testing1 the plan or coverage makes a determination with respect to a request for such authorization not later than #gb hours 7or #bd hours1 in the case the provider submitting such request attests that delay of such testing beyond #bd hours would place an individual's life or health at serious risk7 after receiving such request2 7#d7 in the case such plan or coverage fails to make a determination with respect to a prior authorization request for such testing in accordance with paragraph 7#c71 the plan or coverage treats such request as having been approved2 7#e7 the plan or coverage does not apply any step therapy requirement prior to providing benefits for such testing2 and 7#f7 such benefits are provided in a manner that promotes equitable access1 including for rural and underserved populations1 and supports the use of minimally invasive testing where clinically appropriate4 7c7 ,alzheimer's biomarker testing defined 7#a7 ,in general ,for purposes of this section1 the term ,alzheimer's biomarker testing means the analysis of an individual's tissue1 blood1 or other biospecimen for the presence of a biomarker1 including single-analyte tests1 multiplex panel tests1 protein expression1 and whole genome1 whole exome1 and whole transcriptome sequencing1 furnished for a purpose specified in paragraph 7#b7-- 7,a7 in accordance with any ,food and ,drug ,administration labeling indication2 7,b7 to determine eligibility for1 or to manage treatment of ,alzheimer's disease with1 a drug approved by the ,food and ,drug ,administration2 7,c7 in accordance with any national coverage determination under title ,,xviii of the ,social ,security ,act2 or 7,d7 in accordance with applicable clinical practice guidelines or consensus statements relating to the diagnosis of1 treatment selection for1 management of1 or monitoring of ,alzheimer's disease4 7#b7 ,purposes specified ,for purposes of paragraph 7#a71 the purposes specified in this paragraph are the early detection1 risk stratification1 diagnosis1 treatment1 appropriate management1 or ongoing monitoring of ,alzheimer's disease4 7#c7 ,additional definitions ,for purposes of paragraph 7#a73 7,a7 ,biomarker ,the term biomarker means a characteristic that is objectively measured and evaluated as an indicator of normal biological processes1 pathogenic processes1 or pharmacologic responses to a specific therapeutic intervention1 including gene-drug interactions4 7,b7 ,consensus statement ,the term consensus statement means statements developed by an independent1 multidisciplinary panel of experts that uses a transparent methodology and reporting structure and include a conflict-of-interest policy4 7,c7 ,clinical practice guideline ,the term clinical practice guideline means an evidence-based guideline developed by an independent organization or medical professional society that uses a transparent methodology and reporting structure and includes a conflict-of-interest policy4 4 7#b7 ,effective date ,the amendment made by this subsection shall apply with respect to plan years beginning on or after the date that is #a year after the date of the enactment of this ,act4 7b7 ,medicaid 7#a7 ,inclusion as medical assistance ,section #aije7;a7 of the ,social ,security ,act 7#db ,u4,s4,c4 #acif;d7a77 is amended-- 7,a7 in paragraph 7#ca71 by striking and at the end2 7,b7 by redesignating paragraph 7#cb7 as paragraph 7#cc72 and 7,c7 by inserting after paragraph 7#ca7 the following new paragraph3 7#cb7 biomarker testing 7as defined in section #bgcj7;c7 of the ,public ,health ,service ,act72 and 4 7#b7 ,mandatory coverage ,section #aijb7;a77#aj77;,a7 of the ,social ,security ,act 7#db ,u4,s4,c4 #acie;a7a77#aj77;,a77 is amended1 in the matter preceding clause 7i71 by striking and 7#cj7 and inserting 7#cj71 and 7#cb74 7#c7 ,manner of coverage ,section #aijb7;a7 of the ,social ,security ,act 7#db ,u4,s4,c4 #acif;a7a77 is amended-- 7,a7 in paragraph 7#hi71 by striking and at the end2 7,b7 in paragraph 7#ij71 by striking the period at the end and inserting 2 and2 and 7,c7 by inserting after paragraph 7#ij7 the following new paragraph3 7#ia7 provide1 in the case of biomarker testing 7as defined in subsection 7c7 of section #bgcj of the ,public ,health ,service ,act71 for coverage of such testing in the same manner as such testing is required to be covered by a group health plan or health insurance issuer offering group or individual health insurance coverage under subsection 7b7 of such section4 4 7#d7 ,effective date ,the amendments made by this subsection shall apply with respect to calendar quarters beginning on or after the date that is #a year after the date of the enactment of this ,act4 7c7 ,report ,not later than #a year after the date of the enactment of this ,act1 and on an annual basis for the #b succeeding years1 the ,director of the ,national ,institutes of ,health shall1 through contract with the ,national ,academies of ,sciences1 ,engineering1 and ,medicine1 conduct a study and submit to ,congress a report on the value of biomarker testing in detecting and treating ,alzheimer's disease4